Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.
Clin Pharmacol Ther
; 95(6): 592-7, 2014 Jun.
Article
em En
| MEDLINE
| ID: mdl-24598717
ABSTRACT
Cystic fibrosis (CF) is a life-shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that potentiates CFTR gating function and is specifically indicated for CF patients with a particular CFTR variant, G551D-CFTR (rs75527207). Here, we provide therapeutic recommendations for ivacaftor based on preemptive CFTR genotype results.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Quinolonas
/
Regulador de Condutância Transmembrana em Fibrose Cística
/
Fibrose Cística
/
Aminofenóis
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article